Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting.  Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.

Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.

Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Science

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Share Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)

Sign up to save your podcasts

Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)

Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)

More shows like OncoPharm

JAMA Clinical Reviews

The Daily

Up First from NPR

Armchair Expert with Dax Shepard

ASCO Guidelines

The Peter Attia Drive

OncLive® On Air

Raising Good Humans

Oncology Today with Dr Neil Love

Huberman Lab

The Money with Katie Show

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions

WolverHeme Happy Hour

Good Hang with Amy Poehler